Doogan Declan 4
4 · TENAX THERAPEUTICS, INC. · Filed Dec 12, 2024
Insider Transaction Report
Form 4
Doogan Declan
Director
Transactions
- Award
Stock Option (right to buy)
2024-12-10+100,000→ 100,000 totalExercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (100,000 underlying)
Holdings
- 4
Stock Option (right to buy)
Exercise: $992.00From: 2023-06-09Exp: 2032-06-09→ Common Stock (4 underlying) - 2,274
Common Stock
- 4
Stock Option (right tob buy)
Exercise: $3200.00From: 2022-06-10Exp: 2031-06-10→ Common Stock (4 underlying)
Footnotes (3)
- [F1]The aggregate number of shares of common stock were previously reported as 3,637,871, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
- [F2]These options were previously reported as covering 6,250 shares at an exercise price of $2.00 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.
- [F3]These options were previously reported as covering 5,000 shares at an exercise price of $0.62 per share, but were adjusted to reflect the stock splits that occurred on January 4, 2023 and January 2, 2024.